Search

Your search keyword '"Marciani, M. G."' showing total 324 results
Start Over Author "Marciani, M. G."
324 results on '"Marciani, M. G."'

1. Adaptive Brain Interfaces

Author

Millán, J. del R., Mouriño, J., Heikkonen, J., Kaski, K., Babiloni, F., Marciani, M. G., Topani, F., Canale, I., Goos, Gerhard, editor, Hartmanis, Juris, editor, van Leeuwen, Jan, editor, Mira, José, editor, and Sánchez-Andrés, Juan V., editor

Published
1999
Full Text
View/download PDF

30. Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies

Author

Romigi, A., Albanese, M., Liguori, C., Placidi, F., Marciani, M. G., and Massa, R.

Subjects
musculoskeletal diseases, Article Subject, mental disorders
Abstract

Myotonic dystrophy is the most common type of muscular dystrophy in adults and is characterized by progressive myopathy, myotonia, and multiorgan involvement. Two genetically distinct entities have been identified, myotonic dystrophy type 1 (DM1 or Steinert’s Disease) and myotonic dystrophy type 2 (DM2). Myotonic dystrophies are strongly associated with sleep dysfunction. Sleep disturbances in DM1 are common and include sleep-disordered breathing (SDB), periodic limb movements (PLMS), central hypersomnia, and REM sleep dysregulation (high REM density and narcoleptic-like phenotype). Interestingly, drowsiness in DM1 seems to be due to a central dysfunction of sleep-wake regulation more than SDB. To date, little is known regarding the occurrence of sleep disorders in DM2. SDB (obstructive and central apnoea), REM sleep without atonia, and restless legs syndrome have been described. Further polysomnographic, controlled studies are strongly needed, particularly in DM2, in order to clarify the role of sleep disorders in the myotonic dystrophies.

Published
2013
Full Text
View/download PDF

33. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy

Author

Brodie, M. J, Perucca, E, Ryvlin, P, Ben Menachem, E, Meencke, H. J, Van Landegem, W, Ossemann, M, Sadzot, B, Van Paesschen, W, Van Zandijcke, M, Hovorka, J, Marusic, P, Pazdera, L, Rektor, I, Stolcova, E, Tislerova, D, Kalviainen, R, Korpelainen, J, Peltola, J, Ranua, J, Geraud, G, Hirsch, E, Josien, E, Vercueil, L, Vespignani, H, Jeschke Rohrich, B, Keidel, M, Mattern, W, Ochs, G, Schmitz, B, Schumann, G, Balogh, A, Clemens, B, Czopf, J, Halasz, P, Rajna, P, Vecsei, L, Baruzzi, A, Beghi, A. E, Canevini, M. P, De Feo, M. R, Lamberti, P, Marciani, M. G, Marrosu, F, Mazza, Salvatore, Monaco, F, Mutani, R, Regesta, G, Zaccara, G, Drozdowski, W, Fryze, W, Jedrzejczak, J, Nowaki, P, Selmaj, K, Stelmasiak, Z, Wajgt, A, Bryer, A, Coetzee, C, Gardiner, J, Haug, P, Isaacs, M, Kelbe, C, Modi, G, Opperman, D, Shah, N, Wolberg, S, Arbizu, T, Forcadas, I, Macin Eiras, J. L, Martinez, M, Marti Masso, J. F, Molins, A, Serratosa, J. M, Borre, B, Kallen, K, Kumlien, E, Lindberger, M, Palm, R, Carpay, J. A, Sanders, E. A. C. M, Van Leusden, J. A, Vecht, C, Roberts, R. C, Smith, P, and Tidswell, P.

Subjects
business.industry, levetiracetam, oxcarbazepine, Carbamazepine, medicine.disease, law.invention, Epilepsy, Settore MED/26 - NEUROLOGIA, Tolerability, Randomized controlled trial, law, Anesthesia, Clinical endpoint, Medicine, epilepsy, Neurology (clinical), Levetiracetam, business, Adverse effect, Oxcarbazepine, medicine.drug
Abstract

Objective: We report the results of a prospective study of the efficacy and tolerability of levetiracetam, a new antiepileptic drug with a unique mechanism of action, in comparison with controlled-release carbamazepine as first treatment in newly diagnosed epilepsy. Methods: Adults with ≥2 partial or generalized tonic–clonic seizures in the previous year were randomly assigned to levetiracetam (500 mg twice daily, n = 288) or controlled-release carbamazepine (200 mg twice daily, n = 291) in a multicenter, double-blind, noninferiority, parallel-group trial. If a seizure occurred within 26 weeks of stabilization, dosage was increased incrementally to a maximum of levetiracetam 1,500 mg twice daily or carbamazepine 600 mg twice daily. Patients achieving the primary endpoint (6-month seizure freedom) continued on treatment for a further 6-month maintenance period. Results: At per-protocol analysis, 73.0% (56.6%) of patients randomized to levetiracetam and 72.8% (58.5%) receiving controlled-release carbamazepine were seizure free at the last evaluated dose (adjusted absolute difference 0.2%, 95% CI −7.8% to 8.2%) for ≥6 months (1 year). Of all patients achieving 6-month (1-year) remission, 80.1% (86.0%) in the levetiracetam group and 85.4% (89.3%) in the carbamazepine group did so at the lowest dose level. Withdrawal rates for adverse events were 14.4% with levetiracetam and 19.2% with carbamazepine. Conclusions: Levetiracetam and controlled-release carbamazepine produced equivalent seizure freedom rates in newly diagnosed epilepsy at optimal dosing in a setting mimicking clinical practice. This trial has confirmed in a randomized, double-blind setting previously uncontrolled observations that most people with epilepsy will respond to their first-ever antiepileptic drug at low dosage.

Published
2007

38. ASPICE: an interface system for independent life

Author

Aloise, F., Cincotti, F., Babiloni, F., Marciani, M. G., Morelli, D., Paolucci, S., Oriolo, G., Andrea Cherubini, Sciarra, F., Mangiola, F., Melpignano, A., Davide, F., Mattia, D., Fondazione Santa Lucia [IRCCS], Clinical and Behavioral Neurology [IRCCS Santa Lucia], Dept. Human Physiology, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Dipartimento di Informatica e Sistemistica [Rome], Unione Italiana Lotta alla Distrofia Muscolare, and Telecom Italia

Subjects
Ambient Intelligence, Brain-Computer Interfaces, Severe Motor Impairment, Technologies for Independent Life, [INFO.INFO-RB]Computer Science [cs]/Robotics [cs.RO], Robotic Navigation
Abstract

International audience; In the framework of the ASPICE project, a hardware/software system has been developed, which allows the neuromotor disabled persons to improve or recover their mobility (directly or by emulation) and communication within the surrounding environment. The system pivots around a software controller running on a personal computer, which offers to the user a proper interface to communicate through input interfaces matched with the individual's residual abilities. The system uses the user's input to control domotic devices-such as remotely controlled lights, TV sets, etc.-and a Sony AIBO robot. Preliminary results of a clinical validation are reported.

Published
2006

44. Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients

Author

Pierantozzi, M, Pietroiusti, A, Sancesario, G, Lunardi, G, Fedele, Ernesto, Giacomini, P, Frasca, S, Galante, A, Marciani, M. G., and Stanzione, P.

Subjects
Levodopa, Antiparkinson Agents, Helicobacter pylori, Malabsorption Syndromes, Area Under Curve, Humans, Parkinson Disease, Settore MED/26 - Neurologia, Middle Aged, Aged, Helicobacter Infections
Published
2001

46. EEG-based detection of mental states

Author

Babiloni, Fabio, Cincotti, Febo, Bianchi, L., Pirri, G., Millan, J., Mourino, J., Salinari, Serenella, and Marciani, M. G.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results